Venessa Vuia

The plaintiffs brought a motion to certify a class action against the manufacturers of the antidepressant Celexa (citalopram), alleging the drug caused congenital malformations when ingested by pregnant women and that the defendants failed to warn of this risk.

The court found that while the pleadings disclosed a cause of action and there was an identifiable class, the proposed common issue regarding the duty to warn lacked commonality because the risk of birth defects varied widely and individual causation issues would dominate.

The court concluded a class proceeding was not the preferable procedure due to the inevitability of complex individual trials, and dismissed the certification motion.

The plaintiffs brought a motion for certification of a class action against the manufacturers of Pradaxa, an anticoagulant drug.

The plaintiffs alleged that the defendants breached their duty to warn consumers and healthcare professionals about the lack of an antidote for the drug, which could lead to excessive bleeding.

The court dismissed the certification motion, finding that the plaintiffs failed to establish that the proposed common issues actually existed or could be answered in common across the class.

The court noted that the decision to prescribe an anticoagulant and the need for a reversal agent are highly patient-specific, and there was no basis in fact to conclude that the absence of an antidote posed a common and material risk across the class.

The plaintiff brought a proposed class action against Walmart Canada Inc. and PNI Digital Media Inc. following a data breach at Walmart's online photocentre.

The parties reached a settlement agreement providing for credit monitoring and reimbursement of out-of-pocket expenses up to a combined maximum of $750,000.

The plaintiff brought a motion on consent to certify the action as a class proceeding for settlement purposes.

The court found that all criteria under section 5(1) of the Class Proceedings Act, 1992 were met and granted the motion.